Model N

Overview

Model N, Inc. is a cloud software company founded in 1999 by Zack Rinat, holding a dominant position in a narrow but strategically critical niche: revenue management and government pricing compliance for pharmaceutical and medtech manufacturers. Its platform automates the end-to-end process from drug pricing strategy through Medicaid rebate remittance — a workflow that is mandatory for any manufacturer participating in U.S. federal drug programs, highly regulated, and consequential enough that errors translate directly into multi-million-dollar liability.

Model N went public on the NYSE (ticker: MODN) in March 2013 and was taken private by Vista Equity Partners on June 27, 2024, in an all-cash transaction valued at approximately $1.25 billion ($30.00 per share). The company now operates as a privately held Vista portfolio company.

Current CEO: Bret Connor, appointed January 6, 2025 — previously EVP and COO at athenahealth, overseeing global operations and revenue cycle services across 10,000+ clients and $2 billion in annual revenue. Additional post-acquisition leadership: Chris Crucitti (Chief Growth Officer, Oct 2025), Dan Koellhofer (CPO, Jan 2026), David Schur (CTO, Jan 2026), Amar Jani (CFO, 2025), Angel Rogers (CCO, 2025).

Scale: Platform manages over $1 trillion in revenue and has processed more than $193 billion in chargebacks and rebates combined, across 150+ customers in 120+ countries. Named accounts include Pfizer, AstraZeneca, Johnson & Johnson, Stryker, and Novartis.

Services & Capabilities

Model N’s commercial offering is organized under its Revenue Cloud for Pharma platform — a purpose-built SaaS suite spanning pricing strategy, contract management, government compliance, and channel analytics. This is not a horizontal CRM or ERP play; the value proposition is depth in pharmaceutical-specific regulatory workflows that are legally mandated and carry significant penalty exposure.

Core Product Modules

Government Pricing — The regulatory spine. Manufacturers must calculate and report AMP, Best Price, ASP, and related metrics to CMS monthly and quarterly. Model N constructs reproducible calculation methodologies with full audit trails, automates reporting, and manages government pricing to six or more decimal places of precision.

Medicaid Rebate Processing — End-to-end MDRP workflow: claims ingestion, validation, URA calculation, dispute management, and quarterly remittance. Built-in regulatory update packs keep pace with CMS rule changes. Validates aggregated and prescription-level utilization data to reduce overpayments.

340B Management & Validata — Calculates 340B ceiling prices, communicates via EDI to wholesalers, verifies covered entity eligibility, reconciles chargebacks. Validata performs script-level validation — up to 56 validation checks per line item — catching duplicate discount claims. The 340B Vigilance add-on specifically identifies and blocks “double dip” scenarios.

Payer Management — Automates commercial payer and PBM contracting: formulary-based rebate calculations, price protection, admin fees, and payer roster management.

Provider Management — Manages hospital, GPO, and IDN contract pricing and chargeback processing. Includes Strategy Designer for tiered pricing and rebate structures.

State Price Transparency Management — Centralized repository of state-specific rules with auto-generated compliance reports.

Global Pricing & Tender Management — International Reference Pricing (IRP) risk management and government hospital tender bid preparation for non-U.S. markets.

Intelligence Cloud — Analytics layer: dashboards, alerts, scenario modeling, gross-to-net forecasting, rebate liability reconciliation, and managed care contract performance analytics.

Expert Services (~27% of FY2023 revenues) — Business process outsourcing, application services, M&A integration support.

Who Uses Model N

Within a pharma commercial operations organization, Model N is the system of record across: Government Affairs/Regulatory (CMS price reporting, 340B ceiling prices), Finance/Accounting (GTN accrual management, Medicaid rebate liability), Managed Care/Payer Strategy (PBM/health plan contracting, formulary compliance), Trade/Channel (GPO/wholesaler/IDN chargebacks, 340B eligibility verification), and Legal/Compliance (audit trail generation, DOJ/OIG documentation).

Competitive Position

Model N occupies a defensible niche with few true peers of comparable breadth.

vs. IntegriChain: The closest competitor. IntegriChain’s ICyte platform competes on GTN forecasting, accrual management, and channel data analytics. IntegriChain differentiates on depth of GTN-specific functionality and managed services; Model N’s breadth across government pricing, Medicaid processing, 340B, and commercial contracting in a single system is the primary differentiator. Some manufacturers run both.

vs. IQVIA: IQVIA offers an Orchestrated GTN platform within its broader data ecosystem. Its GTN offering is newer and sits alongside dozens of other products, which can create prioritization challenges. Teams needing both IQVIA data and operational GTN processing often use IntegriChain for the operational layer.

vs. In-house + ERP: Large pharma may attempt GTN on SAP or Oracle ERP. Viable for top-10 but regulatory complexity (IRA, 340B, state transparency) has increased cost and risk of home-grown solutions.

Structural moat: The compliance workflows Model N automates — AMP/Best Price reporting, Medicaid URA calculation, 340B chargeback processing — are legally non-optional. Switching cost is extreme: migrating requires reconstructing years of pricing history, reconfiguring calculation methodologies, and re-validating audit trails. This creates 115-138% net dollar retention and durable relationships with top-25 pharma companies. The IRA has created significant additional demand — 94% of pharma manufacturers surveyed anticipated IRA would impact revenue management programs.

Recent Developments

June 2024 — Vista Equity Take-Private. $1.25 billion ($30.00/share), ~5.0x FY2023 revenue, ~25x forward EBITDA. Premium reflects mission-critical positioning, high switching costs, and meaningful pricing power.

January 2025 — Bret Connor Named CEO. Brings athenahealth operational experience — relevant analog for Model N’s compliance-as-a-service model.

October 2025 — Chris Crucitti Joins as Chief Growth Officer. Signals focus on accelerating go-to-market.

January 2026 — CPO and CTO Appointed. Dan Koellhofer (CPO) and David Schur (CTO) specifically to accelerate AI-driven product innovation.

March 2026 — CCX Partnership for Global Market Access. Strategic partnership with CCX (Switzerland/Portland) connecting CCX’s pre-launch market access planning and payer negotiation tools into Model N’s global pricing and tender solutions. Extends the platform into the pre-commercial phase — manufacturers can model cross-market launch sequencing, MFN exposure, and international reference pricing impacts before implementation.

February 2026 — State of Revenue Report. 99% of life sciences leaders say GTN complexity has increased — driven by IRA, state transparency laws, and data visibility gaps.

IRA Compliance Demand. Medicare drug price negotiation first negotiated prices took effect January 2026. Additional waves follow annually. IRA inflation-based Medicare rebates also require Model N’s structured calculation infrastructure.

Financial Profile

Last complete public financials: FY2023 (ended September 30, 2023).

Metric	FY2023	FY2022	YoY Growth
Total Revenue	$249.5M	$218.7M	+14%
Subscription Revenue	$181.4M	$159.0M	+14%
Professional Services Revenue	$68.1M	~$59.7M	+14%
SaaS ARR (Q4 exit rate)	$131.2M	$109.2M	+20%
Gross Margin (GAAP)	57%	56%	+1pp
Adjusted EBITDA	$42.9M	$32.0M	+34%
Adjusted EBITDA Margin	~17%	~15%	+2pp
Non-GAAP Net Income	$43.0M	$26.5M	+62%

SaaS net dollar retention reached 118.2% in Q4 FY2023. Guiding FY2024 full-year revenue to $260-263M with EBITDA of $48-51M.

Vista Acquisition: $30.00/share, total enterprise value ~$1.25B. ~23% premium over 30-day VWAP. Trailing revenue multiple ~5.0x, forward EBITDA multiple ~25.3x. Vista’s typical 4-7 year hold suggests potential exit in 2028-2031 window.

Sources

• Vista Equity acquisition announcement, FY2023 earnings (Business Wire), Bret Connor CEO appointment, CCX partnership, Scope Research multiples analysis, Model N pharma solutions overview (PDF), Wikipedia
• Perplexity Wave 2 Agent 17 enrichment (raw/research/03_model_n.md)